DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mozobil (Plerixafor Subcutaneous) - Life Threatening Events - Suspected Cause - Side Effect Reports

 
 



Index of reports > Life Threatening Events (19)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mozobil (Plerixafor Subcutaneous) life threatening events. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Mozobil side effects in female

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-22

Patient: female

Reactions: Pulmonary Embolism, Deep Vein Thrombosis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil
    Indication: Lymphoma Transformation

Mozobil
    Dosage: 15.36 mg, qd
    Indication: Haematopoietic Stem Cell Mobilisation
    Start date: 2011-04-27
    End date: 2011-04-29

Other drugs received by patient: Neupogen; Terbinafine HCL; Centyl MED Kaliumklorid; Acyclovir



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-08-21

Patient: female, weighing 25.0 kg (55.0 pounds)

Reactions: Ischaemia, Pulmonary Alveolar Haemorrhage, Pericardial Effusion, Renal Failure, Cardiac Failure, Respiratory Failure, Sepsis, Pleural Effusion, Hypertension, Fusarium Infection

Adverse event resulted in: death, life threatening event, disablity

Drug(s) suspected as cause:
Clolar
    Dosage: 70 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-10
    End date: 2012-01-11

Fludara
    Dosage: 140 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-11
    End date: 2012-06-15

Mozobil
    Dosage: 6 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-16
    End date: 2012-06-18

Thymoglobulin
    Dosage: 254 mg, qd
    Start date: 2012-06-16
    End date: 2012-06-19

Thymoglobulin
    Dosage: 229.9 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-15
    End date: 2012-01-18

Other drugs received by patient: Meropenem; Fentanyl Citrate; Cytarabine; Thiotepa; Melphalan Hydrochloride; Dilaudid; Busulfan



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-08-21

Patient: female, weighing 25.0 kg (55.0 pounds)

Reactions: Ischaemia, Pulmonary Alveolar Haemorrhage, Pericardial Effusion, Renal Failure, Respiratory Failure, Cardiac Failure, Sepsis, Pleural Effusion, Fusarium Infection, Hypertension

Adverse event resulted in: death, life threatening event, disablity

Drug(s) suspected as cause:
Clolar
    Dosage: 70 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-10
    End date: 2012-01-11

Fludara
    Dosage: 140 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-11
    End date: 2012-06-15

Mozobil
    Dosage: 6 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-16
    End date: 2012-06-18

Thymoglobulin
    Dosage: 229.9 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-15
    End date: 2012-01-18

Thymoglobulin
    Dosage: 254 mg, qd
    Start date: 2012-06-16
    End date: 2012-06-19

Other drugs received by patient: Busulfan; Thiotepa; Dilaudid; Meropenem; Cytarabine; Melphalan Hydrochloride; Fentanyl Citrate



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-08-16

Patient: female, weighing 25.2 kg (55.4 pounds)

Reactions: Ischaemia, Pulmonary Alveolar Haemorrhage, Pericardial Effusion, Renal Failure, Cardiac Failure, Respiratory Failure, Sepsis, Pleural Effusion, Fusarium Infection, Hypertension

Adverse event resulted in: death, life threatening event, disablity

Drug(s) suspected as cause:
Clolar
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-10
    End date: 2012-01-11

Fludara
    Dosage: 140 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-11
    End date: 2012-06-15

Mozobil
    Dosage: 6 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-16
    End date: 2012-06-18

Thymoglobulin
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-15
    End date: 2012-01-18

Thymoglobulin
    Dosage: unk
    Start date: 2012-06-16
    End date: 2012-06-19

Other drugs received by patient: Melphalan Hydrochloride; Busulfan; Fentanyl; Thiotepa; Cytarabine; Dilaudid; Meropenem



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-08-13

Patient: female, weighing 25.2 kg (55.4 pounds)

Reactions: Ischaemia, Pulmonary Alveolar Haemorrhage, Pericardial Effusion, Renal Failure, Respiratory Failure, Cardiac Failure, Sepsis, Pleural Effusion, Fusarium Infection, Hypertension

Adverse event resulted in: death, life threatening event, disablity

Drug(s) suspected as cause:
Clolar
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-10
    End date: 2012-01-11

Fludara
    Dosage: 140 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-11
    End date: 2012-06-15

Mozobil
    Dosage: 6 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-16
    End date: 2012-06-18

Thymoglobulin
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-15
    End date: 2012-01-18

Thymoglobulin
    Dosage: unk
    Start date: 2012-06-16
    End date: 2012-06-19

Other drugs received by patient: Meropenem; Melphalan Hydrochloride; Cytarabine; Busulfan; Dilaudid; Fentanyl; Thiotepa



Possible Mozobil side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-24

Patient: female, weighing 85.9 kg (189.0 pounds)

Reactions: White Blood Cell Count Decreased, Acute Myeloid Leukaemia, Pulmonary Alveolar Haemorrhage, Febrile Neutropenia, Lung Infection Pseudomonal, Pseudomonal Bacteraemia, Multi-Organ Failure, Respiratory Failure, Platelet Count Decreased, Cardiac Arrest, Septic Shock

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil

Other drugs received by patient: Neupogen; Carvedilol; Cefpodoxime Proxetil; Polyethylene Glycol; Valacyclovir Hydrochloride; Furosemide; Fluconazole; Temazepam; Fluticasone W; Tramadol HCL; Lansoprazole; Nifedipine; Nifedipine; Docusate Sodium W; Ondansetron Hydrochloride; Potassium Chloride; Levothyroxine Sodium; Sorafenib; Heparin; Lisinopril



Possible Mozobil side effects in female

Reported by a physician from Denmark on 2012-06-07

Patient: female

Reactions: Pulmonary Embolism

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil
    Dosage: unk
    Indication: Haematopoietic Stem Cell Mobilisation
    Start date: 2011-04-27
    End date: 2011-04-29

Mozobil
    Indication: Lymphoma Transformation

Other drugs received by patient: Neupogen; Centyl MED Kaliumklorid; Acyclovir; Terbinafine HCL



Possible Mozobil side effects in female

Reported by a physician from Denmark on 2012-05-31

Patient: female

Reactions: Pulmonary Embolism

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil
    Indication: Lymphoma Transformation

Mozobil
    Dosage: unk
    Indication: Haematopoietic Stem Cell Mobilisation
    Start date: 2011-04-27
    End date: 2011-04-29

Other drugs received by patient: Centyl MED Kaliumklorid; Neupogen; Terbinafine HCL; Acyclovir



Possible Mozobil side effects in 59 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-23

Patient: 59 year old female

Reactions: Sinusitis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Granulocyte Colony Stimulating Factor
    Dosage: 10 mcg/kg, qd; days 1-5
    Indication: Myelodysplastic Syndrome

Mozobil
    Dosage: days 1-5
    Indication: Myelodysplastic Syndrome

Vidaza
    Dosage: 75 mg/m2, qd; days 1-5
    Indication: Myelodysplastic Syndrome



Possible Mozobil side effects in male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-05-17

Patient: male, weighing 110.0 kg (242.0 pounds)

Reactions: Anaphylactic Reaction

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Mozobil

Other drugs received by patient: Granulocyte Colony Stimulating Factor



Possible Mozobil side effects in male

Reported by a physician from United Kingdom on 2012-05-02

Patient: male, weighing 110.0 kg (242.0 pounds)

Reactions: Anaphylactic Reaction

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Mozobil

Other drugs received by patient: Granulocyte Colony Stimulating Factor



Possible Mozobil side effects in male

Reported by a physician from United Kingdom on 2012-04-17

Patient: male, weighing 110.0 kg (242.0 pounds)

Reactions: Anaphylactic Reaction

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Mozobil



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-04-17

Patient: female, weighing 59.7 kg (131.3 pounds)

Reactions: Pulmonary Embolism, Deep Vein Thrombosis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-03-08

Daunorubicin HCL
    Indication: Acute Myeloid Leukaemia

Mozobil
    Dosage: 480 mcg/kg, qd
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-01-08
    End date: 2011-01-13

Neocon
    Dosage: unk
    Indication: Vaginal Haemorrhage
    Start date: 2011-02-09
    End date: 2011-02-09

Other drugs received by patient: Meropenem; Allopurinol; Flagyl; Abelcet; Acyclovir; Provera; Vancomycin



Possible Mozobil side effects in female

Reported by a physician from United States on 2012-03-13

Patient: female, weighing 59.7 kg (131.3 pounds)

Reactions: Pulmonary Embolism, Deep Vein Thrombosis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-03-08

Daunorubicin HCL
    Indication: Acute Myeloid Leukaemia

Mozobil
    Dosage: 480 mcg/kg, qd
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-01-08
    End date: 2011-01-13

Neocon
    Dosage: unk
    Indication: Vaginal Haemorrhage
    Start date: 2011-02-09
    End date: 2011-02-09

Other drugs received by patient: Meropenem; Acyclovir; Abelcet; Flagyl; Allopurinol; Provera; Vancomycin



Possible Mozobil side effects in male

Reported by a physician from Korea, Republic of on 2012-01-27

Patient: male, weighing 20.4 kg (44.9 pounds)

Reactions: Interstitial Lung Disease, Febrile Neutropenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil
    Dosage: 4.7 mg, qd
    Indication: Haematopoietic Stem Cell Mobilisation
    Start date: 2010-11-14
    End date: 2010-11-15

Mozobil
    Indication: Medulloblastoma

Other drugs received by patient: Neupogen



Possible Mozobil side effects in male

Reported by a consumer/non-health professional from Korea, Republic of on 2012-01-20

Patient: male, weighing 20.4 kg (44.9 pounds)

Reactions: Interstitial Lung Disease, Febrile Neutropenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil
    Indication: Medulloblastoma

Mozobil
    Dosage: 4.7 mg, qd
    Indication: Haematopoietic Stem Cell Mobilisation
    Start date: 2010-11-14
    End date: 2010-11-15

Other drugs received by patient: Neupogen



Possible Mozobil side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2011-12-07

Patient: female

Reactions: Myelodysplastic Syndrome

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Alkeran
    Dosage: 16 milligram
    Administration route: Oral
    Start date: 2007-10-01
    End date: 2008-01-01

Alkeran
    Dosage: 200 mg/m2 depending on cycle
    Administration route: Oral
    Start date: 2003-10-01
    End date: 2003-10-01

Cyclophosphamide
    Dosage: 4ug/m2 depending on cylce
    Start date: 2003-05-27
    End date: 2003-05-27

Dexamethasone
    Administration route: Oral
    Start date: 2003-02-01
    End date: 2003-08-01

Dexamethasone
    Dosage: depending on cycle
    Administration route: Oral
    Start date: 2009-12-12
    End date: 2010-10-01

Doxorubicin HCL
    Start date: 2003-02-01
    End date: 2003-01-01

Granocyte
    Dosage: 800 ug, depending on cycle
    Start date: 2011-06-12
    End date: 2011-06-18

Mozobil
    Dosage: depending on cycle
    Start date: 2011-06-13
    End date: 2011-06-16

Prednisolone
    Dosage: 170 milligram
    Administration route: Oral
    Start date: 2007-10-01
    End date: 2008-01-01

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Start date: 2009-12-12
    End date: 2010-10-01

Velcade
    Dosage: depending on cycle
    Start date: 2007-10-01
    End date: 2008-01-01

Vincristine
    Start date: 2003-02-01
    End date: 2003-08-01



Possible Mozobil side effects in male

Reported by a physician from Korea, Republic of on 2011-12-02

Patient: male, weighing 20.4 kg (44.9 pounds)

Reactions: Interstitial Lung Disease, Febrile Neutropenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil

Other drugs received by patient: Neupogen



Possible Mozobil side effects in male

Reported by a consumer/non-health professional from Korea, Republic of on 2011-10-25

Patient: male, weighing 20.4 kg (44.9 pounds)

Reactions: Interstitial Lung Disease, Febrile Neutropenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Mozobil

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017